Xeris Biopharma Holdings, Inc.
XERS
$4.16
$0.215.32%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 67.51% | -4.89% | 20.94% | -41.75% | -9.85% |
| Total Depreciation and Amortization | 0.29% | -0.95% | -1.87% | -1.38% | -2.92% |
| Total Amortization of Deferred Charges | 2.62% | -0.50% | 40.84% | 8.73% | -7.71% |
| Total Other Non-Cash Items | 27.30% | -30.64% | 680.69% | 219.95% | -109.21% |
| Change in Net Operating Assets | -170.33% | 119.90% | 39.87% | -132.17% | 258.03% |
| Cash from Operations | 123.78% | 19.74% | 49.03% | -371.76% | 151.14% |
| Capital Expenditure | -152.87% | 78.09% | -142.07% | -24.24% | 61.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.35% | 100.02% | 125.66% | -229.91% | 0.00% |
| Cash from Investing | 1.03% | 115.38% | 123.42% | -232.16% | 1.45% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | 200.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | 54.68% | -- | -- |
| Repurchase of Common Stock | -100.00% | -62.75% | 98.51% | -6,908.16% | 31.94% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -200.00% | 200.00% | -898.40% | -- |
| Cash from Financing | 579.52% | -112.59% | -98.13% | 2,952.03% | -1,613.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 711.86% | 130.00% | -6.87% | -122.55% | 78,266.67% |
